The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $843,376 in first-year total cost, median $421,688.
Most frequent study sections
- Special Emphasis Panel[ZDA1 IXR-N (A2)]2
Most frequent institutions
- STATE UNIVERSITY OF NEW YORK AT BUFFALO1
- UNIVERSITY OF TENNESSEE HEALTH SCI CTR1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Neuropeptide S Receptor 1 as a Novel Target for Reducing Opioid Self-Administration and Opioid Relapse1R21DA062022-01 | TUNSTALL, BRENDAN | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $423,500 | ZDA1 |
| 2024 | Preclinical Trial: Targeting the Neuropeptide S Receptor to Curb Opioid Taking and Seeking1R21DA061784-01 | CLARK, STEWART DONALDSON | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $419,876 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.